Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aurinia Pharmaceuticals Inc. (T:AUP)

Business Focus: Bio Therapeutic Drugs

Log in or join to add this stock to your watch list.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 1203-4464 Markham St
Tel: N/A
IR: See website
Key People
George M. Milne
Executive Chairman of the Board
Peter S. Greenleaf
Chief Executive Officer, Director
Dennis Bourgeault
Chief Financial Officer, Corporate Secretary
Michael R. Martin
Chief Operating Officer
Neil Solomons
Chief Marketing Officer
Celia Economides
Associate Vice President, Corporate Communications & Patient Advocacy
Robert B. Huizinga
Vice President - Clinical Affairs
Lawrence D. Mandt
Vice President - Regulatory and Quality
Business Overview
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
Financial Overview
For the six months ended 30 June 2019, Aurinia Pharmaceuticals Inc revenues remained flat at $59K. Net loss decreased 9% to $28.3M. Revenues reflect market conditions. Lower net loss reflects Change in estimated fair value of deriva increase from $4.6M (expense) to $2.4M (income), Interest income increase of 83% to $1.6M (income), Amortization of acquired intellectual decrease of 13% to $693K (expense).
Employees: 39 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $553.85M as of Jun 30, 2019
Annual revenue (TTM): $0.61M as of Jun 30, 2019
EBITDA (TTM): -$78.91M as of Jun 30, 2019
Net annual income (TTM): -$81.30M as of Jun 30, 2019
Free cash flow (TTM): -$68.22M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 91,829,758 as of Aug 7, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization